Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

Author：            

Publisher： Spandidos Publications

ISSN： 1019-6439

Source： International Journal of Oncology, Vol.44, Iss.1, 2014-01, pp. : 17-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen

By            

International Journal of Oncology, Vol. 44, Iss. 6, 2014-01 ,pp. : 1820-1830

Spandidos Publications

Access to resources Recommend Favorite

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study

By Kochi Mitsugu   Akiyama Yuji   Aoki Tatsuya   Hagiwara Ken   Takahashi Takao   Hironaka Katsuji   Teranishi Futoshi   Osuka Fumihiko   Takeuchi Masahiro   Fujii Masashi   Nakajima Toshifusa  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1097-1102

Springer Publishing Company

Access to resources Recommend Favorite

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

By Rocha Lima Caio M.   Bayraktar Soley   Flores Aurea M.   MacIntyre Jessica   Montero Alberto   Baranda Joaquina C.   Wallmark John   Portera Chia   Raja Rajiv   Stern Howard   Royer-Joo Stephanie   Amler Lukas C.  

Cancer Investigation, Vol. 30, Iss. 10, 2012-12 ,pp. : 727-731

Informa Healthcare

Access to resources Recommend Favorite

Taxol as Second-Line Treatment in Patients with Advanced Ovarian Cancer after Platinum-Based First-Line Chemotherapy

By Mayerhofer K.   Kucera E.   Zeisler H.   Speiser P.   Reinthaller A.   Sevelda P.  

Gynecologic Oncology, Vol. 64, Iss. 1, 1997-01 ,pp. : 109-113

Elsevier

Access to resources Recommend Favorite